Pasar al contenido principal

BIOSENSORES OPTIMIZADOS PARA UNA MEJOR SELECCION DE CANDIDATOS A FARMACO PARA LA ESCLEROSIS LATERAL AMIOTROFICA

PID2021-128340OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION IMDEA NANOCIENCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale

  • Fernández, Paula
  • Pérez de la Lastra, C.
  • Tosat-Bitrian, Carlota
  • Bueso de Barrio, Jesús Alejandro
  • Thompson, Sebastian
  • Sot, Begoña
  • Salas, Gorka
  • Somoza, Álvaro
  • Espinosa, Ana
  • Castellanos, Milagros
  • Palomo, Valle
49 p.-7 fig.-9 tab., The new and unique possibilities that nanomaterials offer have greatly impacted biomedicine, from the treatment and diagnosis of diseases, to the specific and optimized delivery of therapeutic agents. Technological advances in the synthesis, characterization, standardization, and therapeutic performance of nanoparticles have enabled the approval of several nanomedicines and novel applications. Discoveries continue to rise exponentially in all disease areas, from cancer to neurodegenerative diseases. In Spain, there is a substantial net of researchers involved in the development of nanodiagnostics and nanomedicines. In this review, we summarize the state of the art of nanotechnology, focusing on nanoparticles, for the treatment of diseases in Spain (2017–2022), and give a perspective on the future trends and direction that nanomedicine research is taking., This work has been partially supported by MCIN/AEI /10.13039/501100011033 and European Union NextGenerationEU/PRTR (PID2021-128340OA-I00, PID2020-119352RB-I00, PID2021-127033OB-C21 and RTI2018-101050-J-I00), Comunidad de Madrid (S2022/BMD-7403 RENIM-CM and Talento program 2018-T1/IND-1005), European Union’s Horizon 2020 research and innovation programme (grant agreement No 685795), la Caixa Foundation LCF/PR/HA21/52350003, Asociación Española Contra el Cáncer IDEAS21989THOM, MCIN/AEI/10.13039/501100011033 and “ESF investing in your future” (RYC2019-027489-I, RYC2020-029282-I). CTB thanks Ministerio de Educación (FPU18/06310) for the predoctoral fellowship. IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centers of Excellence in R&D (MINECO, CEX2020-001039-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001039-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosis

  • Cuevas, Eva P.
  • Martínez-González, Loreto
  • Gordillo, Clara
  • Tosat-Bitrian, Carlota
  • Pérez de la Lastra, Carmen
  • Sáenz, Amets
  • Gil, Carmen
  • Palomo, Valle
  • Martín-Requero, Ángeles
  • Martínez Gil, Ana
16 p.-10 fig.-2 tab., Amyotrophic lateral sclerosis is a fatal neurodegenerative disease without a cure to reverse its progression. Its main hallmark is the nuclear protein TDP-43, which undergoes different post-translational modifications leading to a loss of function in the nucleus and an increase in toxicity in the cytoplasm. Previous reports have indicated that pathogenic TDP-43 exhibits prion-like propagation in various contexts. With the aim of advancing therapeutics focused on preventing the propagation of TDP-43 pathology, we studied the potential role of pathogenic TDP-43 in lymphoblasts from sporadic ALS patients. We used lymphoblastoid cell lines from sporadic ALS patients as a source of pathogenic forms of TDP-43, and healthy human cells (lymphoblasts, myoblasts, neuroblastoma SH-SY5Y, or osteosarcoma U2OS) as recipient cells to investigate the seeding and spread of TDP-43 proteinopathy. Furthermore, we evaluated the potential of targeting TDP-43 phosphorylation with a CK-1 inhibitor to prevent the propagation of the pathology. The results presented herein indicate that pathogenic forms of TDP-43 are secreted into the extracellular medium of sporadic ALS lymphoblasts and could be transported by extracellular vesicles, spreading TDP-43 pathology to healthy cells. Moreover, tunneling nanotubes have also been discovered in pathological cells and may be involved in the transport of TDP-43. Interestingly, targeting TDP-43 phosphorylation with an in-house designed CK-1 inhibitor (IGS2.7) was sufficient to halt TDP-43 pathology transmission, in addition to its known effects on restoring the homeostasis of TDP-43 protein in patients-derived cells., Funding support from La Caixa and Luzón Foundation (grant no. HR21–00931), MCIN/AEI /10.13039/501100011033 (grant no. PID2019-105600RB-I00 to A.M. and E.P·C. and PID2021-128340OA-I00, CNS2022–135852 and RYC2019–027489-I to V.P.), Consejo Superior de Investigaciones Cientificas (PTI+ Neuroaging, European Union Next Generation EU/PRTR), Spanish Health Institute Carlos III (grant no. CB18/05/00040 to E.P.C, L.M-G, C. T-B., V.P., A.M.R. and A.M.) and Ministerio de Educación (grant no FPU18/06310 to C.T.B.) are acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteome aggregation in cells derived from amyotrophic lateral sclerosis patients for personalized drug evaluation

  • Pérez de la Lastra, Carmen
  • Tosat-Bitrian, Carlota
  • Porras, Gracia
  • Dafinca, Ruxandra
  • Muñoz-Torrero, Diego
  • Talbot, Kevin
  • Martín-Requero, Ángeles
  • Martínez Gil, Ana
  • Palomo, Valle
9 p.-8 fig.-1 tab. 1 graph. abst., Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that currently lacks effective therapy. Given the heterogeneity of clinical and molecular profiles of ALS patients, personalized diagnostics and pathological characterization represent a powerful strategy to optimize patient stratification, thereby enabling personalized treatment. Immortalized lymphocytes from sporadic and genetic ALS patients recapitulate some pathological hallmarks of the disease, facilitating the fundamental task of drug screening. However, the molecular aggregation of ALS has not been characterized in this patient-derived cellular model. Indeed, protein aggregation is one of the most prominent features of neurodegenerative diseases, and therefore, models to test drugs against personalized pathological aggregation could help discover improved therapies. With this work, we aimed to characterize the aggregation profile of ALS immortalized lymphocytes and test several drug candidates with different mechanisms of action. In addition, we have evaluated the molecular aggregation in motor neurons derived from two hiPSC cell lines corresponding to ALS patients with different mutations in TARDBP. The results provide valuable insight into the different characterization of sporadic and genetic ALS patients’ immortalized lymphocytes, their differential response to drug treatment, and the usefulness of proteome homeostasis characterization in patients’ cells., This work was partially funded by Fundación HNA (I ALS award), Fundación la Caixa (“LCF/TR/CI19/52460012”, “LCF/BQ/PR18/11640007”, and “HR21−00931”), grants RYC2019−027489-I, PID2021−128340OA-I00, and PID2020−118127RB-I00, funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future” (grant RYC2019−027489-I) and “European Union NextGenerationEU/PRTR” (PID2021−128340OA-I00). C.T.B. thanks Ministerio de Educación (FPU18/06310) for the predoctoral fellowship and EMBO Short-Term Fellowship Exchange Program (8856)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Illuminating microtubule functions with small molecules: past, present and future of fluorescent tubulin-binding probes

  • París-Ogáyar R.
  • Lucena-Agell D
  • Altmann K.-H.
  • Palomo V.
  • Díaz J.F.
Developing tools for the real-time visualization of tubulin, microtubules, and their dynamics is essential for studying key cellular processes such as cell division, migration, and differentiation. In this context, fluorescent small-molecule probes that bind to distinct and specific sites on microtubules have significantly advanced our understanding of tubulin dynamics and functions. In addition, fluorescent probes targeting tubulin have enabled the development of high-throughput screening assays to identify novel anti-tubulin compounds. In this review, we present a comprehensive overview of currently available fluorescent molecules that bind to tubulin, detailing their chemical structures, binding sites, development strategies and relevance to the study of microtubule functions. We also explore future directions in this field and highlight key fluorescent probes that are still lacking. Developing these tools would enable the investigation of tubulin's diverse cellular roles in even greater depth and support the advancement of tubulin-targeted therapeutics, This work was partially funded by grants RYC2019-027489-I (VP), PID2021-128340OA-I00 (VP) and PID2022-136765OB-I00 (JFD) from the Ministerio de Ciencia e Innovación (MICIN) and FEDER as well as CNS2022-135852 (VP) from MCIN/AEI/ 10.13039/501100011033, FSE invierte en tu futuro, and the European Union NextGenerationEU/PRTR., Peer reviewed, Sin experimentacion animal ni uso de NAMs
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lighting Up Mislocalized Proteins: Quantum Dot Probes for Multiplexed Cytoplasm-Selective Cell Profiling in Neurodegeneration

  • Fernández-Gómez, Paula
  • Tosat-Bitrian, Carlota
  • Marugán, Tania
  • Fernández-Hernández, Laura
  • Cano, Alicia
  • Martinez-Mulero, Jose A.
  • López-Carbonero, Juan I.
  • Pignatelli, Jaime
  • Corrochano, Silvia
  • Palomo, Valle
Semiconductor quantum dots (QDs) provide unique stability, brightness, and multiplexed capacity for biomarker detection in complex diseases; however, their distinctive intracellular distribution has rarely been leveraged for spatially resolved diagnostics. Here, we show how QD-based sensors enable selective detection of cytoplasmic proteins and can quantify nucleo-cytoplasm protein mislocalization in patient-derived samples. We validated this approach labeling TAR DNA-binding protein 43 (TDP-43), a key mislocalized protein in amyotrophic lateral sclerosis (ALS). Spatial resolution is achieved in several patient-derived models and mouse brain tissue, underscoring the nanosensor's versatility across biological systems. Multiplexed QD-based immunolabeling, combined with confocal imaging and high-throughput flow cytometry, enables the detection of distinct cytoplasmic biomarker signatures that discriminate ALS patients from healthy controls. These signatures include variations in TDP-43 mislocalization and protein coexpression patterns, which were further modulated by pharmacological treatment. This work establishes QDs as spatially selective, multiplexable nanosensors capable of resolving subtle yet disease-relevant intracellular phenotypes in patient-derived samples. Compared to organic fluorophores, QDs enhance sensitivity, improve signal stability, and enable simultaneous spatially resolved biomarker quantification, broadening their potential for clinical diagnostics and personalized medicine. These findings establish QDs as powerful tools for neurodegeneration research, disease monitoring, and early biomarker discovery, with potential applications in translational neuroscience and precision medicine., Peer reviewed, Modelo experimental animal